Taking Stock Of Qiagen

There are many potential entry points to the molecular diagnostics business: biomarker discovery, laboratory operations, instrumentation development, even disease management. Companies in these various sectors are customizing their own approaches to molecular diagnostics and personalized medicines, combining M&A, licensing, and internal R&D to develop what they believe are core opportunities. ( See "Leveraging Assay Platforms to Create Category-Killer Diagnostic Tests," IN VIVO , December 2009 Also see "Leveraging Assay Platforms to Create Category-Killer Diagnostic Tests " - In Vivo, 1 December, 2009. and "Molecular Diagnostics – From Tools to Tests," IN VIVO , May 2006 Also see "Molecular Diagnostics--From Tools to Tests" - In Vivo, 1 May, 2006..)

Qiagen NV, for its part, has used its leading position in nucleic acid-based sample preparation to gain a foothold in the space. Over the past five years it has...